Tri Locum Partners LP: JAZZ PHARMACEUTICALS PLC (JAZZ): Quarterly 13F Position History
As of Q2 2026, Tri Locum Partners LP reported 221,720 shares of JAZZ PHARMACEUTICALS PLC (JAZZ), worth $53.4M and representing 6.6% of its 13F equity book. Quarter-over-quarter share count change: + 63,057 (+39.7%) . The position first appeared in Q1 2021 and has been disclosed across 22 13F-HR filings in Pactolio's tracked window.
- 221,720Shares Held (Latest Filing)
- $53.4MReported Market Value (Latest Filing)
- 6.6%Portfolio Weight (% of 13F Equity Book)
- +63,057Quarter-over-Quarter Share Change
- +$23.4MQuarter-over-Quarter Value Change
- 221,720Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 22 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 221,720 | +63,057 | +39.7% | $53.4M | 6.6% | $241.0 |
| Q1 2026 | 158,663 | +158,663 | – | $30.0M | 4.2% | $189.1 |
| Q4 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 161,812 | -100.0% | $0 | 0.0% | – |
| Q4 2024 | 161,812 | +161,812 | – | $19.9M | 4.1% | $123.2 |
| Q3 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2023 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2022 | 0 | 106,528 | -100.0% | $0 | 0.0% | – |
| Q3 2022 | 106,528 | +49,165 | +85.7% | $14.2M | 4.1% | $133.3 |
| Q2 2022 | 57,363 | 73,315 | -56.1% | $8.9M | 3.7% | $156.0 |
| Q1 2022 | 130,678 | +130,678 | – | $20.3M | 7.9% | $155.7 |
| Q4 2021 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2021 | 0 | 89,370 | -100.0% | $0 | 0.0% | – |
| Q2 2021 | 89,370 | 21,012 | -19.0% | $15.9M | 6.6% | $177.6 |
| Q1 2021 | 110,382 | – | – | $18.1M | 5.8% | $164.4 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a JAZZ position in 13F-HR filings?
Tri Locum Partners LP first reported JAZZ PHARMACEUTICALS PLC (JAZZ) on its 13F-HR filing for the period ending 2021-03-31 (Q1 2021). The position has appeared on 22 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in JAZZ?
Between Q1 2026 and Q2 2026, Tri Locum Partners LP added 63,057 shares of JAZZ (+39.7%), bringing the total reported position to 221,720 shares at a market value of $53.4M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in JAZZ?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.